The Susceptibility of Pseudomonas aeruginosa Strains from Cystic Fibrosis Patients to Bacteriophages

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Essoh, Christiane ^a,b   Blouin, Yann ^a,b   Loukou, Guillaume ^c   Cablanmian, Arsher ^c   Lathro, Serge ^c   Kutter, Elizabeth ^d   Thien, Hoang Vu ^e   Vergnaud, Gilles ^a,b,f   Pourcel, Christine ^a,b  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b CNRS   (France)

^c UFR des Sciences Medicales   (Côte d’Ivoire)

^d EVERGREEN STATE COLLEGE   (United States)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^f DGA/MRIS Mission Pour la Recherche et L'Innovation Scientifique   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIOPHAGE DNA;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENOME; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIOPHAGE; BACTERIUM ISOLATION; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; CONTROLLED STUDY; CYSTIC FIBROSIS; ELECTRON MICROSCOPY; GENE CLUSTER; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; NONHUMAN; NUCLEOTIDE SEQUENCE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; SHORT INTERSPERSED REPEAT;

BACTERIOPHAGES; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS; CRISPR-CAS SYSTEMS; CYSTIC FIBROSIS; GENE ORDER; GENOME, VIRAL; HUMANS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; VIRAL PLAQUE ASSAY;

BACTERIA (MICROORGANISMS); PSEUDOMONAS AERUGINOSA;

EID: 84876548481     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060575     Document Type: Article

References (62)

1. He J, Baldini RL, Deziel E, Saucier M, Zhang Q, et al. (2004) The broad host range pathogen Pseudomonas aeruginosa strain PA14 carries two pathogenicity islands harboring plant and animal virulence genes. Proc Natl Acad Sci U S A 101: 2530-2535.
2. Rahme LG, Stevens EJ, Wolfort SF, Shao J, Tompkins RG, et al. (1995) Common virulence factors for bacterial pathogenicity in plants and animals. Science 268: 1899-1902.
3. Davies JC, Bilton D, (2009) Bugs, biofilms, and resistance in cystic fibrosis. Respir Care 54: 628-640.
4. Lipuma JJ, (2010) The changing microbial epidemiology in cystic fibrosis. Clin Microbiol Rev 23: 299-323.
5. Kutter E, De Vos D, Gvasalia G, Alavidze Z, Gogokhia L, et al. (2010) Phage therapy in clinical practice: treatment of human infections. Curr Pharm Biotechnol 11: 69-86.
6. Abedon ST, Kuhl SJ, Blasdel BG, Kutter EM, (2011) Phage treatment of human infections. Bacteriophage 1: 66-85.
7. Chanishvili N, (2012) Phage therapy-history from Twort and d'Herelle through Soviet experience to current approaches. Adv Virus Res 83: 3-40.
8. Miedzybrodzki R, Borysowski J, Weber-Dabrowska B, Fortuna W, Letkiewicz S, et al. (2012) Clinical aspects of phage therapy. Adv Virus Res 83: 73-121.
9. Brussow H, (2012) Pseudomonas biofilms, cystic fibrosis, and phage: a silver lining? MBio 3.
10. Alemayehu D, Casey PG, McAuliffe O, Guinane CM, Martin JG, et al. (2012) Bacteriophages phiMR299-2 and phiNH-4 can eliminate Pseudomonas aeruginosa in the murine lung and on cystic fibrosis lung airway cells. MBio 3: e00029-00012.
11. Kutateladze M, Adamia R, (2008) Phage therapy experience at the Eliava Institute. Med Mal Infect 38: 426-430.
12. Ceyssens PJ, Lavigne R, (2010) Bacteriophages of Pseudomonas. Future Microbiol 5: 1041-1055.
13. Pirnay JP, De Vos D, Verbeken G, Merabishvili M, Chanishvili N, et al. (2011) The phage therapy paradigm: pret-a-porter or sur-mesure? Pharm Res 28: 934-937.
14. Krylov V, Pleteneva E, Bourkaltseva M, Shaburova O, Volckaert G, et al. (2003) Myoviridae bacteriophages of Pseudomonas aeruginosa: a long and complex evolutionary pathway. Res Microbiol 154: 269-275.
15. Kwan T, Liu J, Dubow M, Gros P, Pelletier J, (2006) Comparative genomic analysis of 18 Pseudomonas aeruginosa bacteriophages. J Bacteriol 188: 1184-1187.
16. Pleteneva EA, Shaburova OV, Sykilinda NN, Miroshnikov KA, Krylov SV, et al. (2008) [Study of the diversity in a group of phages of Pseudomonas aeruginosa species PB1 (Myoviridae) and their behavior in adsorbtion-resistant bacterial mutants]. Genetika 44: 185-194.
17. Hyman P, Abedon ST, (2010) Bacteriophage host range and bacterial resistance. Adv Appl Microbiol 70: 217-248.
18. Stern A, Sorek R, (2011) The phage-host arms race: shaping the evolution of microbes. Bioessays 33: 43-51.
19. Koskella B, Lin DM, Buckling A, Thompson JN, (2012) The costs of evolving resistance in heterogeneous parasite environments. Proc Biol Sci 279: 1896-1903.
20. Labrie SJ, Samson JE, Moineau S, (2010) Bacteriophage resistance mechanisms. Nat Rev Microbiol 8: 317-327.
21. Pourcel C, Salvignol G, Vergnaud G, (2005) CRISPR elements in Yersinia pestis acquire new repeats by preferential uptake of bacteriophage DNA, and provide additional tools for evolutionary studies. Microbiology 151: 653-663.
22. Barrangou R, Fremaux C, Deveau H, Richards M, Boyaval P, et al. (2007) CRISPR provides acquired resistance against viruses in prokaryotes. Science 315: 1709-1712.
23. Sorek R, Kunin V, Hugenholtz P, (2008) CRISPR-a widespread system that provides acquired resistance against phages in bacteria and archaea. Nat Rev Microbiol 6: 181-186.
24. Cady KC, Bondy-Denomy J, Heussler GE, Davidson AR, O'Toole GA, (2012) The CRISPR/Cas Adaptive Immune System of Pseudomonas aeruginosa Mediates Resistance to Naturally Occurring and Engineered Phages. J Bacteriol 194: 5728-5738.
25. Miller RV, Rubero VJ, (1984) Mucoid conversion by phages of Pseudomonas aeruginosa strains from patients with cystic fibrosis. J Clin Microbiol 19: 717-719.
26. Bondy-Denomy J, Pawluk A, Maxwell KL, Davidson AR, (2013) Bacteriophage genes that inactivate the CRISPR/Cas bacterial immune system. Nature 493: 429-432.
27. Vu-Thien H, Corbineau G, Hormigos K, Fauroux B, Corvol H, et al. (2007) Multiple-locus variable-number tandem-repeat analysis for longitudinal survey of sources of Pseudomonas aeruginosa infection in cystic fibrosis patients. J Clin Microbiol 45: 3175-3183.
28. Sobral D, Mariani-Kurkdjian P, Bingen E, Vu-Thien H, Hormigos K, et al. (2012) A new highly discriminatory multiplex capillary-based MLVA assay as a tool for the epidemiological survey of Pseudomonas aeruginosa in cystic fibrosis patients. Eur J Clin Microbiol Infect Dis 31: 2247-2256.
29. Romling U, Wingender J, Muller H, Tummler B, (1994) A major Pseudomonas aeruginosa clone common to patients and aquatic habitats. Appl Environ Microbiol 60: 1734-1738.
30. Scott FW, Pitt TL, (2004) Identification and characterization of transmissible Pseudomonas aeruginosa strains in cystic fibrosis patients in England and Wales. J Med Microbiol 53: 609-615.
31. Larche J, Pouillot F, Essoh C, Libisch B, Straut M, et al. (2012) Rapid identification of international multidrug resistant Pseudomonas aeruginosa clones by multiple locus VNTR analysis (MLVA) and investigation of their susceptibility to lytic bacteriophages. Antimicrob Agents Chemother.
32. Kropinski AM, Prangishvili D, Lavigne R, (2009) Position paper: the creation of a rational scheme for the nomenclature of viruses of Bacteria and Archaea. Environ Microbiol 11: 2775-2777.
33. Zerbino DR, Birney E, (2008) Velvet: algorithms for de novo short read assembly using de Bruijn graphs. Genome Res 18: 821-829.
34. Boisvert S, Laviolette F, Corbeil J, (2010) Ray: simultaneous assembly of reads from a mix of high-throughput sequencing technologies. J Comput Biol 17: 1519-1533.
35. Makarova KS, Aravind L, Wolf YI, Koonin EV, (2011) Unification of Cas protein families and a simple scenario for the origin and evolution of CRISPR-Cas systems. Biol Direct 6: 38.
36. Grissa I, Vergnaud G, Pourcel C, (2007) CRISPRFinder: a web tool to identify clustered regularly interspaced short palindromic repeats. Nucleic Acids Res 35: W52-57.
37. Mathee K, Narasimhan G, Valdes C, Qiu X, Matewish JM, et al. (2008) Dynamics of Pseudomonas aeruginosa genome evolution. Proc Natl Acad Sci U S A 105: 3100-3105.
38. Makarova KS, Haft DH, Barrangou R, Brouns SJ, Charpentier E, et al. (2011) Evolution and classification of the CRISPR-Cas systems. Nat Rev Microbiol 9: 467-477.
39. Cady KC, White AS, Hammond JH, Abendroth MD, Karthikeyan RS, et al. (2011) Prevalence, conservation and functional analysis of Yersinia and Escherichia CRISPR regions in clinical Pseudomonas aeruginosa isolates. Microbiology 157: 430-437.
40. Grissa I, Vergnaud G, Pourcel C, (2008) CRISPRcompar: a website to compare clustered regularly interspaced short palindromic repeats. Nucleic Acids Res 36: W145-148.
41. Tan Y, Zhang K, Rao X, Jin X, Huang J, et al. (2007) Whole genome sequencing of a novel temperate bacteriophage of P. aeruginosa: evidence of tRNA gene mediating integration of the phage genome into the host bacterial chromosome. Cell Microbiol 9: 479-491.
42. Ceyssens PJ, Hertveldt K, Ackermann HW, Noben JP, Demeke M, et al. (2008) The intron-containing genome of the lytic Pseudomonas phage LUZ24 resembles the temperate phage PaP3. Virology 377: 233-238.
43. Garbe J, Bunk B, Rohde M, Schobert M, (2011) Sequencing and characterization of Pseudomonas aeruginosa phage JG004. BMC Microbiol 11: 102.
44. Debarbieux L, Leduc D, Maura D, Morello E, Criscuolo A, et al. (2010) Bacteriophages can treat and prevent Pseudomonas aeruginosa lung infections. J Infect Dis 201: 1096-1104.
45. Hughes KA, Sutherland IW, Clark J, Jones MV, (1998) Bacteriophage and associated polysaccharide depolymerases-novel tools for study of bacterial biofilms. J Appl Microbiol 85: 583-590.
46. Glukhov AS, Krutilina AI, Shlyapnikov MG, Severinov K, Lavysh D, et al. (2012) Genomic analysis of Pseudomonas putida phage tf with localized single-strand DNA interruptions. PLoS One 7: e51163.
47. Magnani E, Sjolander K, Hake S, (2004) From endonucleases to transcription factors: evolution of the AP2 DNA binding domain in plants. Plant Cell 16: 2265-2277.
48. Whichard JM, Weigt LA, Borris DJ, Li LL, Zhang Q, et al. (2010) Complete genomic sequence of bacteriophage felix o1. Viruses 2: 710-730.
49. Thomas JA, Rolando MR, Carroll CA, Shen PS, Belnap DM, et al. (2008) Characterization of Pseudomonas chlororaphis myovirus 201varphi2-1 via genomic sequencing, mass spectrometry, and electron microscopy. Virology 376: 330-338.
50. Sharma M, Ellis RL, Hinton DM, (1992) Identification of a family of bacteriophage T4 genes encoding proteins similar to those present in group I introns of fungi and phage. Proc Natl Acad Sci U S A 89: 6658-6662.
51. Gimble FS, (2000) Invasion of a multitude of genetic niches by mobile endonuclease genes. FEMS Microbiol Lett 185: 99-107.
52. Yuzenkova J, Nechaev S, Berlin J, Rogulja D, Kuznedelov K, et al. (2003) Genome of Xanthomonas oryzae bacteriophage Xp10: an odd T-odd phage. J Mol Biol 330: 735-748.
53. Edgell DR, Gibb EA, Belfort M, (2010) Mobile DNA elements in T4 and related phages. Virol J 7: 290.
54. Morello E, Saussereau E, Maura D, Huerre M, Touqui L, et al. (2011) Pulmonary bacteriophage therapy on Pseudomonas aeruginosa cystic fibrosis strains: first steps towards treatment and prevention. PLoS One 6: e16963.
55. Vieira A, Silva YJ, Cunha A, Gomes NC, Ackermann HW, et al. (2012) Phage therapy to control multidrug-resistant Pseudomonas aeruginosa skin infections: in vitro and ex vivo experiments. Eur J Clin Microbiol Infect Dis 31: 3241-3249.
56. Karumidze N, Thomas JA, Kvatadze N, Goderdzishvili M, Hakala KW, et al. (2012) Characterization of lytic Pseudomonas aeruginosa bacteriophages via biological properties and genomic sequences. Appl Microbiol Biotechnol 94: 1609-1617.
57. Chan BK, Abedon ST, (2012) Phage therapy pharmacology phage cocktails. Adv Appl Microbiol 78: 1-23.
58. Chibani-Chennoufi S, Sidoti J, Bruttin A, Dillmann ML, Kutter E, et al. (2004) Isolation of Escherichia coli bacteriophages from the stool of pediatric diarrhea patients in Bangladesh. J Bacteriol 186: 8287-8294.
59. Kutter E, (2009) Phage host range and efficiency of plating. Methods Mol Biol 501: 141-149.
60. Tejedor C, Foulds J, Zasloff M, (1982) Bacteriophages in sputum of patients with bronchopulmonary Pseudomonas infections. Infect Immun 36: 440-441.
61. Holloway BW, (1969) Genetics of Pseudomonas. Bacteriol Rev 33: 419-443.
62. Edgar R, Qimron U, (2010) The Escherichia coli CRISPR System Protects from {lambda} Lysogenization, Lysogens, and Prophage Induction. J Bacteriol 192: 6291-6294.